NCT07613424Recruiting
A Study of MET Concordance and Gene Profiling in 1L NSCLC (Genomet)
A Multicenter, Prospective Study of MET Concordance and Gene Profiling in First-line Non-small Cell Lung Cancer (NSCLC) (Genomet)
Source: ClinicalTrials.gov · Last updated 26 Oct 2026
Brief summary (registry, in English)
Multicenter prospective assessment of MET concordance and tumor gene profiling in treatment-naïve NSCLC
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 1000 (estimated)
- First submitted
- 7 May 2026
- Start date
- 2 Jun 2026
- Primary completion date
- 31 Mar 2027
- Lead sponsor
- AstraZeneca
- Diseases
- Lung cancer
- NCT number
- NCT07613424
What you commit to
- Study type: Interventional
- Planned participants: 1000
- From 2 Jun 2026 to the primary completion date, 31 Mar 2027
- 42 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior radiotherapy or systemic therapy for unresectable locally advanced (Stage IIIB/IIIC) or metastatic/recurrent (Stage IV) NSCLC, except patients initiating first-line therapy for this specific disease stage within 1 month before ICF signing.
Other illness
- Medical Conditions
- Currently having other malignant tumors, or having other infiltrating malignant tumors in the past 5 years. Stage I malignant tumor after radical treatment for at least 3 years, except those considered by investigators to have a small possibility of recurrence. Participants with radically treated carcinoma in situ (non-infiltrating), papillary thyroid carcinoma and skin cancer other than malignant melanoma can be enrolled.
Who the study is looking for
- Participants are eligible to be included in the study only if all of the following criteria apply:
- Age
- Participant must be ≥ 18 at the time of signing the informed consent. Type of Participant and Disease Characteristics
- Participants who are in accordance with the Eighth Edition of TNM Staging of Lung Cancer by the International Association for the Study of Lung Cancer and American Joint Committee on Cancer, histologically or cytologically confirmed unresectable locally advanced (Stage ⅢB/ⅢC), metastatic or recurrent (Stage IV) NSCLC.
- Willing to provide adequate tissue sample:
- 1Biopsy tissue must be collected after confirmation of unresectable locally advanced (Stage IIIB/IIIC), metastatic, or recurrent (Stage IV) NSCLC diagnosis, and before initiation of any antitumor therapy. The biopsy specimens require at least 16 FFPE slides.
- or 2Surgical specimens only for patients with recurrent disease who either received no adjuvant therapy, or received only adjuvant chemotherapy and recurrence occurred \>6 months after completing chemotherapy. The surgical specimens require at least 13 FFPE slides (surgical specimens obtained within 2 years before ICF signing).
- Informed Consent 4.Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
- 5.Provision of signed and dated, written informed consent form prior to any mandatory study-specific procedures, sampling, and analyses.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (42)
Sites in registry order. Save your city in your profile to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.